Insulin-like growth factor agonist molecules
AssigneeGenentech, Inc.
InventorsRoss G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
Life of this patent
Estimating the term…
Abstract
Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
Claims8
A method for inhibiting binding of insulin-like growth factor binding protein 3 (IGFBP-3) to insulin-like growth factor 1 (IGF-I) in a mammal comprising administering to the mammal an effective amount of a peptide that inhibits binding of IGFBP-3 to IGF-I, said peptide comprising an amino acid sequence that is SEQ ID NO:108.
A method for increasing serum and tissue levels of biologically active IGF-I in a mammal comprising administering to the mammal an effective amount of a peptide that binds IGFBP-3 effective to reduce plasma insulin secretion when administered to a mammal, said peptide comprising an amino acid sequence that is SEQ ID NO:108.
Dependencies are inferred from the claim text.